Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or conce...
TCR2 Therapeutics (NASDAQ:TCRR) reported quarterly losses of $(1.03) per share. This is a 35.53 percent decrease over losses of...
The Dow Jones jumped more than 500 points on Friday. When insiders purchase or sell shares, it indicates their confidence or co...
Mizuho analyst Mara Goldstein downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral and lowers the price target fro...
EF Hutton analyst Tony Butler reiterates TCR2 Therapeutics (NASDAQ:TCRR) with a Hold and maintains $2 price target.
TCR2 Therapeutics (NASDAQ:TCRR) reported quarterly losses of $(1.56) per share. This is a 116.67 percent decrease over losses o...
